About the Authors
- Agnieszka Ciesielska
-
Affiliation Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States of America
- Lluis Samaranch
-
Affiliation Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States of America
- Waldy San Sebastian
-
Affiliation Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States of America
- Dennis W. Dickson
-
Affiliation Mayo Clinic, Jacksonville, FL, United States of America
- Samuel Goldman
-
Affiliation Department of Neurology, University of California San Francisco, San Francisco, CA, United States of America
- John Forsayeth
-
Affiliation Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States of America
- Krystof S. Bankiewicz
-
* E-mail: Krystof.Bankiewicz@ucsf.edu
Affiliation Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States of America
Competing Interests
KSB is a Scientific Founder of Voyager Therapeutics, company that is involved in developing AAV2-AADC gene therapy for Parkinson's Disease. All authors declare that they have no competing interests relating to patents, products in development, or marketed products.
Author Contributions
Conceptualization: JF KSB. Formal analysis: AC LS WSS KSB. Funding acquisition: KSB. Methodology: AC LS WSS. Supervision: KSB. Writing – original draft: AC LS WSS. Writing – review & editing: DWD SG JF KSB.